A Phase I Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Administration of Extended-Release Injectable Suspension (ND-340) as Post-operative Analgesia in Patients With Total Knee Arthroplasty (TKA)
Latest Information Update: 16 Nov 2023
At a glance
- Drugs ND-340 (Primary) ; Morphine
- Indications Postoperative pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nang Kuang Pharmaceutical
- 08 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Jun 2026.
- 08 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 03 Jul 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024.